U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H8O4.2Al.3O
Molecular Weight 282.1191
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALOXIPRIN

SMILES

CC(=O)Oc1ccccc1C(=O)O.[Al+3].[Al+3].[O-2].[O-2].[O-2]

InChI

InChIKey=MXCPYJZDGPQDRA-UHFFFAOYSA-N
InChI=1S/C9H8O4.2Al.3O/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;;;;;/h2-5H,1H3,(H,11,12);;;;;/q;2*+3;3*-2

HIDE SMILES / InChI

Molecular Formula Al
Molecular Weight 26.9815
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C9H7O4
Molecular Weight 179.1498
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CNS Activity

Curator's Comment:: The penetration of the blood-brain barrier was studied in animals.

Originator

Curator's Comment:: Felix Hoffmann discovered aspirin when working for Friedrich Bayer & Co. # Bayer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23219|||Q5T7T7
Gene ID: 5742.0
Gene Symbol: PTGS1
Target Organism: Homo sapiens (Human)
1.2 µM [IC50]
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
5.2 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SYNALGOS-DC

Approved Use

SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Launch Date

-3.62620813E11
Primary
FIORINAL

Approved Use

FIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

Launch Date

2.00016003E11
Preventing
DURLAZA

Approved Use

DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.

Launch Date

1.44132486E12
Preventing
AGGRENOX

Approved Use

AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Launch Date

9.4322878E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.25 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.84 mg/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.31 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.12 mg × h/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.322 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.422 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
68%
ASPIRIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 1242 uM]
yes [Km 2337 uM]
yes [Km 278.6 uM]
yes [Km 40.7 uM]
yes [Km 683.1 uM]
yes [Km 698.2 uM]
yes [Km 94.2 uM]
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Pharmacotherapies for cocaine dependence.
2000 Dec
The discovery of aspirin: a reappraisal.
2000 Dec 23-30
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.
2000 Dec 8
Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema.
2000 Sep
Aspirin induces apoptosis through mitochondrial cytochrome c release.
2000 Sep 1
Novel platelet inhibitors.
2001
Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?
2001
Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking.
2001 Apr
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study.
2001 Feb
Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.
2001 Feb
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
2001 Feb
The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein.
2001 Feb
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.
2001 Feb
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
2001 Feb
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people.
2001 Feb
Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review.
2001 Feb 10
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.
2001 Feb 10
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior.
2001 Jan
Present treatment options for unstable angina and non-Q-wave myocardial infarction.
2001 Jan
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.
2001 Jan
Antithrombotic therapy in atrial fibrillation.
2001 Jan
Use of antithrombotic agents during pregnancy.
2001 Jan
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause.
2001 Jan
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.
2001 Jan
Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses.
2001 Jan
[Leukocytoclastic vasculitis associated with ticlopidine].
2001 Jan
Antithrombotic therapy in cardiac stent patients.
2001 Jan
Anticoagulation and heart failure.
2001 Jan
Is optimal antithrombotic therapy after myocardial infarction well defined?
2001 Jan
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
2001 Jan
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.
2001 Jan
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.
2001 Jan
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
2001 Jan
Prevention of pre-eclampsia: status and perspectives 2000.
2001 Jan
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.
2001 Jan
Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells.
2001 Jan
Another reason for taking aspirin.
2001 Jan
Hypothesized treatment for migraines using low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid.
2001 Jan
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
2001 Jan
Increased platelet reactivity and significant changes in coagulation markers after cavopulmonary connection.
2001 Jan
Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia.
2001 Jan 1
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
2001 Jan 15
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Blood donations and risk of coronary heart disease in men.
2001 Jan 2
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
2001 Jan 2
Authors' reply on aspirin for primary prevention.
2001 Jan 20
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
2001 Jan 23
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.
2001 Jan 5
Drug Points: tachycardia associated with moxifloxacin.
2001 Jan 6
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa.
2001 Mar 9
Patents

Sample Use Guides

In Vivo Use Guide
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration: Enteral
In Vitro Use Guide
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:45:10 UTC 2021
Edited
by admin
on Sat Jun 26 07:45:10 UTC 2021
Record UNII
6QT214X4XU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALOXIPRIN
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ALOXIPRIN [INN]
Common Name English
SUPERPYRIN
Brand Name English
ALOXIPRIN [MART.]
Common Name English
ALOXIPRIN [WHO-DD]
Common Name English
ALAPRIN
Common Name English
PALOXIN
Common Name English
POLYOXYALUMINIUM ACETYLSALICYLATE
Common Name English
POLYOXYALUMINUM ACETYLSALICYLATE
Common Name English
ALOXIPRIN [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AC15
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
WHO-ATC N02BA02
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
WHO-VATC QN02BA02
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
WHO-VATC QB01AC15
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
Code System Code Type Description
DRUG BANK
DB13509
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
RXCUI
17393
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
ALOXIPRIN
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
ChEMBL
CHEMBL2108222
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
INN
1373
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
MERCK INDEX
M1575
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY Merck Index
EPA CompTox
9014-67-9
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
MESH
C010843
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
EVMPD
SUB00370MIG
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
PUBCHEM
71586929
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
DRUG CENTRAL
4760
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
NCI_THESAURUS
C166958
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
FDA UNII
6QT214X4XU
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
CAS
9014-67-9
Created by admin on Sat Jun 26 07:45:10 UTC 2021 , Edited by admin on Sat Jun 26 07:45:10 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY